Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combating KRASG12C Inhibitor Resistance.

Cancer discovery - 12 Jan 2024

Abstract excerpt

To boost KRASG12C inhibitor efficacy and counter cancer cells' ability to mount resistance, combination strategies are being utilized. Findings from the phase III CodeBreaK 300 trial indicate that adding the EGFR inhibitor panitumumab to sotorasib bests standard care for chemorefractory KRASG12C colorectal cancer. Joint SHP2 blockade is another approach that shows signs of activity in reversing acquired KRASG12C...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Colorectal Neoplasms
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Panitumumab

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 37921413
DOI: 10.1158/2159-8290.CD-ND2023-0015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combating KRASG12C Inhibitor Resistance.PMID 37921413Read ↗

Resistance looms for KRAS G12C inhibitors and rational tackling strategies.Semantic proximity Read ↗

Multiple initiatives to conquer KRAS G12C inhibitor resistance from the perspective of clinical therapy.Semantic proximity Read ↗

KRAS inhibitors: resistance drivers and combinatorial strategies.Semantic proximity Read ↗

Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial.Semantic proximity Read ↗

KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies.Semantic proximity Read ↗

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C.Semantic proximity Read ↗

Differential Response and Resistance to KRAS-Targeted Therapy.Semantic proximity Read ↗

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions.Semantic proximity Read ↗

KRAS G12C-mutated Metastatic Colorectal Cancer: Current Therapeutic Strategies and Future Directions.Semantic proximity Read ↗

Assessment of KRASG12C inhibitors for colorectal cancerSemantic proximity Read ↗

The Next Generation of KRAS Targeting: Reasons for Excitement and Concern.Semantic proximity Read ↗

KRAS-Targeted Therapies in NSCLC: Resistance, Combination Strategies, and Emerging Clinical Paradigms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.